SCHEMBL6500579

SCHEMBL6500579

COc1cccc(-c2ccc(C(=O)NC3CC4CC3CN4)s2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.51
HSD17B2 P37059 11/20 0.48
HSD17B1 P14061 9/20 0.47
CHRNA7 P36544 5/20 0.45
HTR3E A5X5Y0 4/20 0.45
HTR3B O95264 4/20 0.45
HTR3A P46098 4/20 0.45
HTR3D Q70Z44 4/20 0.45
HTR3C Q8WXA8 4/20 0.45
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CHEK1 O14757 1/20 0.43
AURKA O14965 1/20 0.43
MAP4K4 O95819 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6486653 0.91 KDM4E (0.55) HSD17B2HSD17B1CHRNA7HTR3EHTR3B
SCHEMBL6490374 0.87 RXFP1 (0.48) HSD17B2HSD17B1CHRNA7HTR3EHTR3B
SCHEMBL6486616 0.86 CHRNA7 (0.58) CHRNA7HTR3EHTR3BHTR3AHTR3D
SCHEMBL6501238 0.85 HPGDS (0.53) HSD17B2HSD17B1CHRNA7HTR3EHTR3B
SCHEMBL6500034 0.85 MAPK11 (0.48) HSD17B2HSD17B1CHRNA7HTR3EHTR3B
SCHEMBL6487125 0.85 HPGDS (0.51) HSD17B2HSD17B1CHRNA7HTR3EHTR3B
SCHEMBL6489231 0.85 ESRRG (0.51) CHRNA7HTR3EHTR3BHTR3AHTR3D
SCHEMBL6487324 0.84 HDAC6 (0.52) HDAC6HSD17B2HSD17B1KDM4ENPC1
SCHEMBL6498904 0.83 HDAC6 (0.50) HDAC6HSD17B2HSD17B1CHRNA7HTR3E
SCHEMBL7232229 0.83 HDAC6 (0.50) HDAC6HSD17B2HSD17B1CHRNA7HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 HDAC6 1069/4885HSD17B2 517/4885HSD17B1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.